
(In thousands)	Plasma		Blood Center		Hospital		Total
Carrying amount as of March 30, 2024	$	29,043	$	33,484	$	502,555	$	565,082
Assets held for sale	—		(4,475)		—		(4,475)
Purchase accounting adjustments	—		—		(19,248)		(19,248)
Acquisitions	—		—		69,542		69,542
Currency translation	—		(268)		(5,367)		(5,635)
Carrying amount as of December 28, 2024	$	29,043	$	28,741	$	547,482	$	605,266

The decrease in goodwill of $19.2 million for purchase accounting adjustments was primarily related to the Company obtaining additional facts and information to finalize the pre-acquisition tax returns and associated analyses for OpSens. This resulted in the Company revising its estimate of the net deferred tax liability recorded as of the acquisition date. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisitions of OpSens and Attune Medical.

In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related goodwill of $4.5 million has been reclassified to Prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.

The gross carrying amount of intangible assets and the related accumulated amortization as of December 28, 2024 and March 30, 2024 is as follows:


(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net

As of December 28, 2024
Amortizable:
Developed technology	$	505,323	$	146,898	$	358,425
Customer contracts and related relationships	136,181		70,261		65,920
Capitalized software	85,528		74,722		10,806
Patents and other	27,504		13,579		13,925
Trade names	15,927		6,136		9,791
Total	$	770,463	$	311,596	$	458,867
Non-amortizable:
In-process software development	$	6,748


Total	$	6,748


(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net

As of March 30, 2024
Amortizable:
Developed technology	$	464,291	$	178,413	$	285,878
Customer contracts and related relationships	255,144		190,033		65,111
Capitalized software	84,837		69,491		15,346
Patents and other	24,504		11,820		12,684
Trade names	14,320		5,456		8,864
Total	$	843,096	$	455,213	$	387,883
Non-amortizable:
In-process research and development	$	13,667

In-process software development	4,567
Total	$	18,234

During fiscal 2025, the Company acquired Attune Medical and recorded $96.1 million of developed technology, $7.8 million of customer contracts and related relationships and $1.9 million of trade name intangibles based on the purchase accounting valuation. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisition.

In the first quarter of fiscal 2025, the Company announced the commercialization of MVP XL and moved the related in-process research and development intangible asset to developed technologies and commenced amortization. In the second quarter of fiscal 2024, the Company recorded an intangible asset impairment charge of $10.4 million related to the intangibles acquired as part of the enicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit.

In the third quarter of fiscal 2025, the Company announced the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were recognized as held for sale. The related intangible assets are fully amortized and have a net book value of zero. The gross intangible assets value is $185.6 million.

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years.

During the three and nine months ended December 28, 2024, amortization expense was $13.9 million and $42.6 million, respectively. During the three and nine months ended December 30, 2023, amortization expense was $9.3 million and $28.5 million, respectively.

Future annual amortization expense on intangible assets for the next five years is estimated to be as follows:


(In thousands)
Remainder of Fiscal 2025	$	12,995
Fiscal 2026	$	49,879
Fiscal 2027	$	47,931
Fiscal 2028	$	46,160
Fiscal 2029	$	44,965